An Exploratory Multicenter, Open-Label, Single Arm Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination With Nintedanib (Ofev) in Patients With Idiopathic Pulmonary Fibrosis
Phase of Trial: Phase IV
Latest Information Update: 25 Jun 2018
At a glance
- Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Genentech; Roche
- 25 Jun 2018 Results published in the European Respiratory Journal.
- 23 May 2018 Results assessing safety and tolerability presented at the 114th International Conference of the American Thoracic Society
- 08 Jun 2017 Status changed from active, no longer recruiting to completed.